Payment overview · 2025
General Payments
$53.80
3 reported records · 3 companies
Healthcare provider profile · identity verified
Paul Jonathan Smith, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSON, TN · NPI 1871527010
Verified facts
What the public records show
CMS Open Payments records show Paul Jonathan Smith, MD received $53.80 in general payments during 2025 across 3 reported records.
Seqirus USA Inc accounted for 47.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $25.36 | 47.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.65 | 27.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.79 | 25.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $53.80 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 250 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 70 |
| Omeprazole | Omeprazole | 180 | 31 |
| Losartan Potassium | Losartan Potassium | 167 | 38 |
| Metformin Hcl | Metformin Hcl | 154 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 149 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 40 |
| Furosemide | Furosemide | 140 | 33 |
| Lisinopril | Lisinopril | 137 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 34 |
| Eliquis | Apixaban | 98 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 17 |
| Cephalexin | Cephalexin | 92 | 82 |
| Gabapentin | Gabapentin | 92 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 12 |
| Potassium Chloride | Potassium Chloride | 70 | 25 |
| Spironolactone | Spironolactone | 66 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 65 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 58 | suppressed |
| Risperidone | Risperidone | 56 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 13 |
| Memantine Hcl Er | Memantine Hcl | 53 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 51 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 30 |
| Trazodone Hcl | Trazodone Hcl | 51 | 13 |
| Ozempic | Semaglutide | 50 | suppressed |
| Prednisone | Prednisone | 49 | 40 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Jardiance | Empagliflozin | 48 | suppressed |
| Simvastatin | Simvastatin | 46 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | suppressed |
| Fluconazole | Fluconazole | 38 | 21 |
| Meloxicam | Meloxicam | 38 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | 11 |
| Tramadol Hcl | Tramadol Hcl | 34 | 16 |
| Glimepiride | Glimepiride | 32 | 11 |
| Atenolol | Atenolol | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | 11 |
| Carvedilol | Carvedilol | 28 | 12 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 14 |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53.80 · 3 records | Seqirus USA Inc | CAPVAXIVE, Fluad, Flucelvax, GARDASIL 9, VAXNEUVANCE, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error